Trius Therapeutics, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 71   

Articles published

TSRX 0.0000
price chart
Trius Therapeutics To Be Acquired By Cubist
Cubist Pharmaceuticals (CBST) and Trius Therapeutics, Inc. (TSRX) announced that they have signed a definitive agreement under which Cubist will acquire all outstanding shares of Trius for $13.50 per share in cash.
Cubist Buys Trius, Optimer for New Hospital Antibiotics  Bloomberg
Related articles »  
Robbins Geller Rudman & Dowd LLP Announces Proposed Settlement of Trius ...
If you held Trius common stock and received consideration for your shares in the acquisition of Trius by Cubist at the price of $13.50 per share in cash and one Contingent Value Right per share, your rights may be affected by the settlement of this Action.
Trius Therapeutics and Bayer Form Strategic Collaboration to Develop and ...
SAN DIEGO, July 27, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) and Bayer Pharma AG today announced that they have signed an exclusive agreement to develop and commercialize Trius' lead Phase 3 antibiotic, torezolid ...
Trius Therapeutics, Inc. (TSRX) Investor Lawsuit to Halt Takeover Announced by ...
SAN DIEGO, Aug. 5, 2013 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that an investor who currently holds Trius Therapeutics, Inc. (TSRX) shares filed a lawsuit to halt the proposed takeover of Trius Therapeutics, Inc. by Cubist ...
Trius Acquired Last Week, Tetraphase Could Be Next  Seeking Alpha
Related articles »  
Trius Therapeutics: Takeover Candidate In 2013
Trius Therapeutics (TSRX) is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections.
Trius Therapeutics to Present Experimental Antibiotic Study Results at ECCMID ...
SAN DIEGO, April 23, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that the results of a large, late-stage human study, called ESTABLISH 2, and multiple other clinical studies from its experimental antibiotic ...
Related articles »  
Cubist Pharmaceuticals Completes Acquisition of Trius Therapeutics
LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it has completed the previously announced acquisition of Trius Therapeutics, Inc. (NASDAQ: TSRX) for an aggregate upfront cash consideration of ...
Related articles »  
Trius Therapeutics: Tedizolid's Potential Commercial Paths
Trius Therapeutics (TSRX) is a small capitalization biotech company developing novel antibiotics. Its lead compound is tedizolid, which is a second generation oxazolidinone in Phase III trials for the treatment of acute bacterial skin and skin ...
Trius Announces Positive Results From ESTABLISH 2 Study of Tedizolid in Severe ...
SAN DIEGO, March 25, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) today announced top-line results from its ESTABLISH 2 Phase 3 clinical trial of tedizolid phosphate (TR-701) for the treatment of acute bacterial skin and skin ...
Related articles »  
Pfizer And Teva Settlement On Generic Zyvox A Significant Positive For Trius ...
On May 31, 2012, Pfizer (NYSE:PFE) and Teva (NYSE:TEVA) reached a settlement on a patent dispute involving Teva's plan to launch a generic version of Pfizer's antibiotic Zyvox (linezolid).